2021
Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support
Crothers K, DeFaccio R, Tate J, Alba PR, Goetz MB, Jones B, King JT, Marconi V, Ohl ME, Rentsch CT, Rodriguez-Barradas MC, Shahrir S, Justice AC, Akgün KM, Group F. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. European Respiratory Journal 2021, 60: 2102532. PMID: 34824060, PMCID: PMC8841623, DOI: 10.1183/13993003.02532-2021.Peer-Reviewed Original ResearchConceptsIntensive respiratory supportHospitalised COVID-19 patientsCOVID-19 patientsNasal cannulaEarly dexamethasoneRespiratory supportSevere acute respiratory syndrome coronavirus 2Low-flow nasal cannulaAcute respiratory syndrome coronavirus 2Coronavirus disease 2019 (COVID-19) patientsRespiratory syndrome coronavirus 2Cox proportional hazards modelUS Veterans Affairs hospitalsSyndrome coronavirus 2Veterans Affairs hospitalProportional hazards modelCOVID-19Prior corticosteroidsCause mortalityMortality benefitTotal patientsCoronavirus 2Unexposed groupReal-world findingsEarly initiationEarly initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Alcorn C, Kidwai-Khan F, Skanderson M, Brittain E, King JT, Ho YL, Eden S, Kundu S, Lann MF, Greevy RA, Ho PM, Heidenreich PA, Jacobson DA, Douglas IJ, Tate JP, Evans SJW, Atkins D, Justice AC, Freiberg MS. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. The BMJ 2021, 372: n311. PMID: 33574135, PMCID: PMC7876672, DOI: 10.1136/bmj.n311.Peer-Reviewed Original ResearchConceptsProphylactic anticoagulationDay mortalityEarly initiationTherapeutic anticoagulationCohort studyInpatient mortalityHospital admissionAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCoronavirus disease 2019 (COVID-19) mortalitySyndrome coronavirus 2 infectionCOVID-19History of anticoagulationSerious bleeding eventsCoronavirus 2 infectionHours of admissionObservational cohort studyRisk of deathCoronavirus disease 2019Real-world evidenceBleeding eventsSubcutaneous heparinHospital stayNationwide cohortCumulative incidence
2009
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. New England Journal Of Medicine 2009, 360: 1815-1826. PMID: 19339714, PMCID: PMC2854555, DOI: 10.1056/nejmoa0807252.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyRisk of deathAsymptomatic patientsHuman immunodeficiency virus (HIV) infectionCubic millimeterEarly-therapy groupImmunodeficiency virus infectionPrevious antiretroviral therapyCohort of patientsClinical characteristicsHIV infectionRelative riskEarly initiationVirus infectionCD4PatientsMedical careTherapyDeathCalendar yearInfectionRiskCountSurvivalGroup
2008
Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.
Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Annals Of Internal Medicine 2008, 148: 178-85. PMID: 18252681, PMCID: PMC3124094, DOI: 10.7326/0003-4819-148-3-200802050-00004.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyViral loadHIV treatmentEarly treatmentEarly initiationLife expectancyVeterans Aging Cohort StudyChronic HIV infectionCombination antiretroviral therapyEarly treatment initiationAging Cohort StudyTherapy-related toxicityAge 40 yearsQuality-adjusted life expectancyAge 30 yearsBase-case analysisCohort studyHIV infectionTreatment initiationCopies/Current recommendationsLate treatmentImportant harmsTherapyTreatment